Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm.
Southlake, Texas (PRWEB) March 05, 2015 -- RMI specializes in Stemnexa™ non-surgical treatment of acute and chronic orthopedic conditions such as meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. Stemnexa may also be administered during orthopedic surgeries to promote better post-surgical outcomes.
Stemnexa combines the latest, patented scientific advances in nearly pain-free bone marrow harvesting with two complimentary cellular technologies: Bone Marrow Aspirate Concentrate (BMAC) and *AlphaGEMS amniotic tissue product.
BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.
*AlphaGEMS product is harvested from donated amniotic sac tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/
Find out more about RMI in the February edition of Society Life Magazine.
Riordan-McKenna Institute
801 E. Southlake Blvd.
Southlake, Texas
76092
Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154
About Neil Riordan PhD
Neil Riordan, PhD is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute. Dr. Riordan is one of the early pioneers and leading experts in cell therapy. Dr. Riordan earned his Bachelor of Science at Wichita State University and graduated magna cum laude. He received his Master’s degree at the University of Nebraska Medical Center. Dr. Riordan earned his Ph.D. in Health Sciences at Medical University of the Americas.
Dr. Riordan has published over 60 scientific articles in international peer-reviewed journals and authored two book chapters on the use of non-controversial stem cells from placenta and umbilical cord. In the stem cell arena, he and his colleagues have published more than 20 articles on Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis, Duchenne Muscular Dystrophy, Autism, and Charcot Marie Tooth Syndrome. In 2007, Dr. Riordan’s research team was the first to discover and document the existence of mesenchymal-like stem cells in menstrual blood. For this discovery, his team was honored with the “Medical Article of the Year Award” from Biomed Central. Other notable journals in which Dr. Riordan has published articles include the British Journal of Cancer, Cellular Immunology, Journal of Immunotherapy, and Translational Medicine.
Dr. Riordan is an accomplished inventor; listed on more the 25 patent families, including 11 issued patents. He is credited with a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr. Hugh Riordan on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin C’s preferential toxicity to cancer cells notably led to a 1997 patent grant for the treatment of cancer with vitamin C. In 2010, Dr. Riordan received another patent for a new cellular cancer vaccine.
He is also the Founder and Chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI’s stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. He is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).
Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting five IRB-approved clinical trials in Panama for multiple sclerosis, rheumatoid arthritis and osteoarthritis using human umbilical cord-derived mesenchymal stem cells, mesenchymal trophic and stromal vascular fraction. Additional trials for spinal cord injury, autism and cerebral palsy are in the works upon IRB approval.
Dr. Riordan’s research team collaborates with a number of universities and institutions, including:
• National Institutes of Health
• Indiana University
• University of California, San Diego
• University of Utah
• University of Western Ontario
• University of Nebraska
Dr. Riordan is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals including Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.
About Wade McKenna, DO
Dr. Wade McKenna is cofounder of the Riordan-McKenna Institute. He is board certified in orthopedic surgery and fellowship trained in trauma and post-traumatic reconstruction. Dr. McKenna is a leading advocate of autologous stem cell therapy and regenerative medicine focusing on advancing the clinical benefits in orthopedics. He has administered stem cell-enriched products to thousands of surgical and non-surgical patients. Successful applications include:
• Long bone non-unions
• Avascular necrosis of the femoral head
• Severe clavicle non-unions
• Cartilage regeneration
• Chondrogenesis and soft tissue repair of the shoulder
• Chronic tendinopathy
• Tendon ruptures
• Foot and ankle injuries
• Wrist fractures
Dr. McKenna is the chief medical officer and co-founder of Biologic Therapies, a product development and research company dedicated to the advancement of autologous adult stem cell therapy. His achievements include the recent development of the BioMac bone marrow aspiration catheter, treating world-class athletes, and developing numerous surgical and non-surgical stem cell application protocols.
After receiving his undergraduate degree and earning his medical degree at Oklahoma State University, Dr. McKenna completed his orthopedic residency at the Dallas/Ft Worth Medical Center and his trauma fellowship at Tampa General Hospital. Dr. McKenna has practiced in the Dallas/Forth-Worth area for over 20 years, most notably at McKenna Orthopedics in Trophy Club, Texas and North Central Texas Orthopedics & Sports Medicine in Decatur, Texas.
Jay D Lenner Jr, Riordan-McKenna Institute, http://www.rmiclinic.com, +1 (817) 776-8155, [email protected]
Share this article